Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Cosentyx Secukinumab ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Cosentyx Secukinumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Jardiance Empagliflozin Diabetes mellitus, type 2 with high cardiovascular risk Reimburse with clinical criteria and/or conditions Complete
Synjardy Empagliflozin and metformin Diabetes mellitus (Type 2) Reimburse with clinical criteria and/or conditions Complete
Viacoram perindopril arginine / amlodipine Hypertension, essential Reimburse with clinical criteria and/or conditions Complete
N/A bevacizumab and lomustine Recurrent glioblastoma multiform Reimburse with clinical criteria and/or conditions Complete
Paxlovid nirmatrelvir/ritonavir Mild-to-moderate COVID-19, treatment Active
Epidiolex cannabidiol Lennox-Gastaut Syndrome (LGS) Active
Epidiolex cannabidiol Dravet Syndrome (DS) Active
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Active